| Latest 3SBio, Sponsored American Deposit Receipt Representing 7 Shares News Headlines | | Date | Time | Source | | | 07/23/2009 | 3:59AM | PRNUS | 3SBio Inc. to Report 2009 Second Quarter Earnings on August 11, 2009
SHENYANG, China, July 23 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (NASDAQ:SSRX), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it will release financial results for the second quarter ended June 30, 2009 after... More...>> |
| 05/05/2009 | 7:52AM | PRNUS | 3SBio Inc. Announces Appointment of Ernst & Young Hua Ming as Independent Auditor
SHENYANG, China, May 5 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (NASDAQ:SSRX) ("3SBio" or "the Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced the appointment of Ernst & Young Hua Ming ("Ernst & Young... More...>> |
| 05/04/2009 | 7:30AM | PRNUS | 3SBio Inc. to Report 2009 First Quarter Earnings on May 19, 2009
SHENYANG, China, May 4 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (NASDAQ:SSRX), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it will release financial results for the first quarter ended March 31, 2009 after... More...>> |
| 03/11/2009 | 5:00PM | PRNUS | 3SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2008 Results
Company Exceeds Guidance with 2008 Revenue of RMB243.2 million (US$35.7
million); Full year 2008 Adjusted Non-GAAP Operating Income Grew 20.6% over
2007 to RMB59.7 million (US$8.8 million)
Provides 2009 Net Revenue Guidance Range of US$43-US$45 million
SHENYANG, China, March 11 /PRNewswire-Asia-FirstCall/... More...>> |
| 02/09/2009 | 8:30AM | PRNUS | 3SBio Inc. Appoints Mr. Bo Tan as Chief Financial Officer
SHENYANG, China, Feb. 9 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (NASDAQ:SSRX), a leading biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China, today announced that it has appointed Mr. Bo Tan as Chief Financial Officer, effective February... More...>> |
| 01/20/2009 | 8:30AM | PRNUS | 3SBio Inc. Files for SFDA Approval for TPIAO Label Extension for the Treatment of ITP
SHENYANG, China, Jan. 20 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (NASDAQ:SSRX), a leading biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China, today announced that it filed on December 30, 2008 with the Chinese State Food and Drug Administration... More...>> |
| 11/24/2008 | 4:30PM | PRNUS | 3SBio Inc. to Present at the Piper Jaffray 20th Annual Health Care Conference
SHENYANG, China, Nov. 24 /PRNewswire/ -- 3SBio Inc. (NASDAQ:SSRX), a leading biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China, announced that Dr. Yingfei Wei, Chief Scientific Officer, will present at the Piper Jaffray 20th Annual Health... More...>> |
| 11/10/2008 | 4:30PM | PRNUS | 3SBio Inc. Announces Third Quarter 2008 Results
SHENYANG, China, Nov. 10 /Xinhua-PRNewswire-FirstCall/ -- 3SBio Inc. (NASDAQ:SSRX) ("3SBio" or the "Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced its unaudited financial results for the third quarter ended... More...>> |
| 11/10/2008 | 8:00AM | PRNUS | 3SBio Inc. Files for SFDA Approval of NuLeusin
SHENYANG, China, Nov. 10 /Xinhua-PRNewswire/ -- 3SBio Inc. (NASDAQ:SSRX), a leading biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China, today announced that it has filed with the Chinese State Food and Drug Administration (SFDA) for approval... More...>> |
| 10/31/2008 | 6:15PM | PRNUS | 3SBio Inc. Announces Preliminary Third Quarter 2008 Results
-- Expects One-Time Impairment Charge of RMB19.0 million (US$2.7 million)
-- Affirms 2008 Full Year Guidance
SHENYANG, China, Oct. 31 /Xinhua-PRNewswire-FirstCall/ -- 3SBio Inc. (NASDAQ:SSRX) ("3SBio" or "the Company"), a leading biotechnology company focused on researching, developing, manufacturing and marketing... More...>> |
| 10/16/2008 | 8:00AM | PRNUS | 3SBio Inc. Schedules 2008 Third Quarter Earnings Release on Monday, November 10, 2008
Earnings Conference Call to be Held on November 11, 2008 at 5:00 am (Pacific)
/ 8:00 am (Eastern) / 9:00 pm (Beijing/Hong Kong)
SHENYANG, China, Oct. 16 /Xinhua-PRNewswire-FirstCall/ -- 3SBio Inc. (NASDAQ:SSRX), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing... More...>> |
| 09/25/2008 | 8:00AM | PRNUS | 3SBio Inc. Files for SFDA Approval of High-dose (36,000 IU) EPIAO
SHENYANG, China, Sept. 25 /Xinhua-PRNewswire-FirstCall/ -- 3SBio Inc. (NASDAQ:SSRX), a leading biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China, today announced that it has filed with the Chinese State Food and Drug Administration (SFDA... More...>> |
| 09/16/2008 | 5:22PM | PRNUS | 3SBio Inc. to Present at the UBS Global Life Sciences Conference
SHENYANG, China, Sept. 16 /Xinhua-PRNewswire-FirstCall/ -- 3SBio Inc. (NASDAQ:SSRX), a leading biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China, announced that David Chen, Chief Operating Officer, will present at the UBS Global Life Sciences... More...>> |
| 08/25/2008 | 4:05PM | PRNUS | 3SBio Inc. to Present at the Morgan Stanley Global Healthcare Unplugged Conference
SHENYANG, China, Aug. 25 /Xinhua-PRNewswire-FirstCall/ -- 3SBio Inc. (NASDAQ:SSRX), a leading biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China, announces that David Chen, Chief Operating Officer will present at the Morgan Stanley Global... More...>> |
| 08/20/2008 | 4:05PM | PRNUS | 3SBio Inc. to Hold Annual General Meeting
SHENYANG, China, Aug. 20 /Xinhua-PRNewswire-FirstCall/ -- 3SBio Inc. (NASDAQ:SSRX), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that the 2008 Annual General Meeting of Shareholders of 3SBio Inc. will be held on... More...>> |
| 08/12/2008 | 4:10PM | PRNUS | 3SBio Inc. Announces Second Quarter 2008 Results
SHENYANG, China, Aug. 12 /Xinhua-PRNewswire-FirstCall/ -- 3SBio Inc. (NASDAQ:SSRX), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced its unaudited financial results for the second quarter ended June 30, 2008.
Second... More...>> |
| 07/29/2008 | 4:05PM | PRNUS | 3SBio Inc. Schedules 2008 Second Quarter Earnings Release On Tuesday, August 12, 2008
Earnings Conference Call to be Held on August 13, 2008
at 5:00 am (Pacific) / 8:00 am (Eastern) / 8:00 pm (Beijing/Hong Kong)
SHENYANG, China, July 29 /Xinhua-PRNewswire-FirstCall/ -- 3SBio Inc. (NASDAQ:SSRX), a leading China-based biotechnology company focused on researching, developing, manufacturing... More...>> |
| 07/01/2008 | 8:30AM | PRNUS | 3SBio Inc. Announces Filing of Annual Report on Form 20-F
SHENYANG, China, July 1 /Xinhua-PRNewswire-FirstCall/ -- 3SBio Inc. (NASDAQ:SSRX), a leading biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China, today announced that it has filed with the SEC an annual report on Form 20-F for the year ended... More...>> |
| 05/28/2008 | 9:43AM | PRNUS | 3SBio Inc. to Present at the Goldman Sachs Twenty-Ninth Annual Global Healthcare Conference
SHENYANG, China, May 28 /Xinhua-PRNewswire-FirstCall/ -- 3SBio Inc. (NASDAQ:SSRX), a leading biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China, announces that David Chen, Chief Operating Officer, and Kevin Teo, Chief Financial Officer will... More...>> |
| 05/27/2008 | 8:30AM | PRNUS | AMAG Pharmaceuticals, Inc. and 3SBio, Inc. Announce Strategic Partnership to Develop and Commercialize Ferumoxytol in China
SHENYANG, China, May 28 /Xinhua-PRNewswire-FirstCall/ -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) and 3SBio, Inc. (NASDAQ:SSRX), a leading Chinese biotechnology company, today announced the signing of a development and commercialization agreement for ferumoxytol, an intravenous iron replacement therapeutic agent being... More...>> |
|